IP Library Granted Patent US 7,326,575
Granted Patent B2
US 7,326,575 · App. 11/283,062 · Granted Feb 5, 2008

Methods and compositions for the preparation and use of fixed-treated cell-lines and tissue in fluorescence in situ hybridization

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,326,575
App. No.
11/283,062
Granted
Feb 5, 2008
Kind
B2
Abstract

This invention relates to methods for the detection of one or more mRNA transcripts in paraffin-embedded tissue by “mRNA liberation in fixed-treated tissue or ‘MLIFTT’”. This method includes treating the tissue with ammonia-ethanol and sodium borohydride combined with pressure cooking of the tissue. The chemical treatments reduce the tissue autofluorescence and the physical treatments overcome the interference created by the fixation-induced chemical bonds. The methods of the present invention can be utilized to identify a plurality of mRNA transcripts in a microarray format.

Claims (30)

1. A method of in situ hybridization for detecting and specifically identifying a plurality of transcription sites in a cell, the method comprising:

(a) treating a sample with ammonia-ethanol and sodium borohydride;

(b) pressure cooking the sample;

(c) assigning a different barcode to more than one different target sequence, wherein each barcode comprises at least one fluorochrome, and at least one barcode comprises at least two different spectrally distinguishable fluorochromes;

(d) providing a probe set specific to the more than one different target sequences containing a hybridization probe specific for each target nucleic acid, each hybridization probe comprising a single nucleic acid molecule complementary to the target sequence, wherein each probe is labeled with a fluorochrome and the fluorochromes in each probe set collectively identify the barcode for the target sequence of that probe set;

(e) incubating the tissue with a set of probes specific for each of the at least two different target sequences such that each hybridization probe simultaneously hybridizes to the target sequence to which each hybridization probe is complementary; and

(f) detecting the fluorochromes on the probe set hybridized to RNA transcribed from each target sequence, if present, thereby separately detecting and specifically identifying the plurality of transcripts, wherein the detecting includes spectrally distinguishing the different fluorochromes, wherein the fluorochromes on a detected transcript constitute a barcode for the detected transcript.

2. The method of claim 1 further comprising quantifying the flurochromes by a computerized detection system.

3. The method of claim 1 wherein the cell has been pretreated with an agent.

4. The method of claim 1 wherein the fluorochromes are selected from the group consisting of Cy2, fluorX, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, fluorescein and Texas Red.

5. The method of claim 3 wherein the probe is an oligonucleotide.

6. The method of claim 3 wherein the probe is a protein nucleic acid.

7. The method of claim 3 wherein the cell is part of a tissue sample.

8. The method of claim 7 wherein the tissue sample is derived from a mammal.

9. The method of claim 8 wherein the mammal is a human.

10. A method for identifying a potential therapeutic agent which modulates a level of a gene's expression in a tissue, the method comprising:

(a) preparing at least a first and second sample from at least a first and second tissue by pressure cooking the sample in a decloaking chamber at a temperature of about 125° C. reaching a pressure of between about 20 to about 24 PSI; and treating the pressure cooked sample with ammonia ethanol in a concentration of about 0.25% and sodium borohydride in a concentration of about 5%; wherein the samples are identical with the exception that the first tissue has been sampled from a cell-line, animal or human that has been treated with the agent whereas the second tissue has been sampled from a cellline, animal, or human that has not been treated with the agent;

(b) detecting the level of the gene's transcription in the at least first and second tissue using FISH,

wherein a difference in the detected levels indicates that the agent modulates the level of the gene's expression.

11. The method according to claim 10 , wherein the modulation of the gene's expression is comprised in a gene pathway associated with therapeutic effects.

12. The method according to claim 10 , wherein the modulation of the gene's expression is comprised in a gene pathway associated with toxic effects.

13. A method for performing fluorescent in situ hybridization comprising the steps of:

a) providing a pressure cooked composition comprising a fixed-treated tissue, ammonia-ethanol; and sodium borohydride;

b) performing fluorescent in situ hybridization with at least one nucleic acid probe to detect a target nucleic acid in said pressure cooked composition.

14. The method according to claim 13 wherein said probe comprises at least two fluorochromes detectable in quantitative computational fluorescence microscopic analysis.

15. The method according to claim 13 wherein said target nucleic acid is mRNA which is hybridized with at least two different labeled probes during said fluorescent in situ hybridization step.

16. The method according to claim 13 wherein said pressure cooked composition is spotted on a microarray during said providing step.

17. The method of claim 13 wherein the method is a toxicology analysis.

18. The method according to claim 15 wherein the mRNA is a pre-mRNA.

19. The method according to claim 15 further comprising a quantification step wherein an mRNA expression level is calculated as a proportion of fluorochrome signal intensity of the mRNA.

Assignments (7)
THIS IS TO CORRECT ERRORS IN A COVER SHEET PREVIOUSLY RECORDED (REEL/FRAME 027502/0828): CORRECTION OF THE ASSIGNOR'S NAME TO AUREON (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC.; CORRECTION OF THE ASSIGNEE'S NAME TO AUREON, INC. Recorded May 22, 2012
From: AUREON (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
To: AUREON, INC.
Reel/Frame 028252/0442 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2012
From: AUREON, INC.
To: CHAMPALIMAUD FOUNDATION
Reel/Frame 028244/0077 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2012
From: AUREON BIOSCIENCES, INC.
To: DAVID SANS
Reel/Frame 027502/0828 →
SECURITY AGREEMENT Recorded Oct 25, 2010
From: AUREON BIOSCIENCES, INC.
To: ATLAS VENTURE FUND VI GMBH & CO. KG; ATLAS VENTURE FUND VI, L.P.; ATLAS VENTURE ENTREPRENEURS' FUND VI, L.P.; PFIZER INC.; MINTZ LEVIN INVESTMENTS LLC; SPROUT CAPITAL IX, L.P.; DLJ CAPITAL CORP.; SPROUT ENTREPRENEURS FUND, L.P.; SPROUT IX PLAN INVESTORS, L.P.; CANTABRIA DE ACTIVOS, S.L.; CORPORACION MASAVEU, S.A.; INICIATIVAS DIGITALES; IPETEX S.A.; INVERSIONES VECU 2006, S.L.; LEALTAD DESARROLLO, S.C.R., S.A.; BASSETTI, MARCO; C+PA-CIMENTO E PRODUTOS ASSOCIADOS, S.A.
Reel/Frame 025178/0899 →
SECURITY AGREEMENT Recorded Aug 9, 2010
From: AUREON BIOSCIENCES, INC.
To: ATLAS VENTURE FUND VI, L.P.; ATLAS VENTURE FUND VI GMBH & CO. KG; ATLAS VENTURE ENTREPRENEURS' FUND VI, L.P.; SPROUT ENTREPRENEURS FUND, L.P.; SPROUT CAPITAL IX, L.P.; DLJ CAPITAL CORP.; SPROUT IX PLAN INVESTORS, L.P.; PFIZER INC; MINTZ LEVIN INVESTMENTS LLC; INICIATIVAS DIGITALES; INVERSIONES VECU 2006, S.L.; LEALTAD DESARROLLO, S.C.R., S.A.; IPETEX S.A.; CANTABRIA DE ACTIVOS, S.L.; CORPORACION MASAVEU, S.A.; PEREZ DE ARMINAN, ALFREDO; FERNANDEZ DE VILLAVICENCIO, GABRIEL STAMOGLOU; FERNANDEZ DE VILLAVICENCIO, ALEJANDRO STAMOGLOU
Reel/Frame 024946/0493 →
SECURITY AGREEMENT Recorded Jan 12, 2010
From: AUREON LABORATORIES, INC.
To: ATLAS VENTURE ENTREPRENEURS' FUND VI, L.P.; ATLAS VENTURE FUND VI GMBH & CO. KG; ATLAS VENTURE FUND VI, L.P.; SPROUT CAPITAL IX, L.P.; DLJ CAPITAL CORP.; SPROUT IX PLAN INVESTORS, L.P.; SPROUT ENTREPRENEURS' FUND, L.P.; PFIZER INC.; CANTABRIA DE ACTIVOS, S.L.; CORPORACION MASAVEU, S.A.; LEALTAD DESARROLLO, S.C.R., S.A.; INICIATIVAS DIGITALES; INVERSIONES VECU 2006, S.L.; MARCO BASSETTI; ESTRELA - SGPS, S.A.; MINTZ LEVIN INVESTMENTS LLC
Reel/Frame 023768/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2006
From: CAPODIECI, PAOLA; EDELSON, JON
To: AUREON LABORATORIES, INC.
Reel/Frame 017679/0369 →